



The association between allostatic load and lymphedema in breast cancer survivors

Barnabas Obeng-Gyasi¹ · Yevgeniya Gokun² · Mohamed I. Elsaid^{2,3,4} · JC Chen⁵ · Barbara L. Andersen⁶ · William E. Carson⁵ · Sachin Jhawar⁷ · Jesus D. Anampa⁸ · Dionisia Quiroga⁴ · Roman Skoracki⁹ · Samilia Obeng-Gyasi⁵

Received: 17 August 2024 / Accepted: 12 March 2025
© The Author(s) 2025

Abstract

Purpose Allostatic load, a measure of physiological dysregulation secondary to chronic exposure to socioenvironmental stressors, is associated with 30-day postoperative complications and mortality in patients with breast cancer. This study aimed to examine the association between allostatic load (AL) at diagnosis and development of breast cancer-related lymphedema (BCRL).

Methods Patients aged 18 years or older who received surgical treatment for stage I-III breast cancer between 2012 and 2020 were identified from The Ohio State University Cancer Registry. AL was calculated using biomarkers from the cardiovascular, metabolic, renal, and immunologic systems. A high AL was defined as AL > median. Logistic regression analyses examined the association between AL and BCRL, adjusting for sociodemographic, clinical, and treatment factors.

Results Among 3,609 patients, 18.86% (n = 681) developed lymphedema. A higher proportion of patients with lymphedema were Black (11.89% vs. 7.38%, $p < 0.0001$), Medicaid insured (12.19% vs. 6.97%, $p < 0.0001$), had stage 3 disease (7.05% vs. 1.57%, $p < 0.0001$), and had a high AL (53.63% vs. 46.90%, $p = 0.0018$). In adjusted analysis, high AL was associated with higher odds of developing lymphedema than low AL (OR 1.281 95% CI 1.06–1.55). Moreover, a 1-unit increase in AL was associated with 10% higher odds of lymphedema (OR 1.10, 95% CI 1.04–1.16). There was no statistically significant association between AL and severity of lymphedema (OR 1.02, 95% CI 0.82–1.23).

Conclusion In this retrospective cohort of breast cancer survivors, high AL at diagnosis was associated with higher odds of developing lymphedema. Future research should elucidate the pathways by which AL influences lymphedema.

Keywords Breast cancer · Allostatic load · Lymphedema · Stress · Survivorship

✉ Samilia Obeng-Gyasi
samilia.obeng-gyasi@osumc.edu

¹ Indiana University School of Medicine, Indianapolis, IN, USA

² Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, OH, USA

³ Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA

⁴ Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

⁵ Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH, USA


⁶ Department of Psychology, The Ohio State University, Columbus, OH, USA

⁷ Department of Radiation Oncology, The Ohio State University, Columbus, OH, USA

⁸ Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

⁹ Division of Reconstructive Oncologic Plastic Surgery, Department of Plastic Surgery, The Ohio State University, Columbus, OH, USA

Fig. 1 Conceptual Framework of the Association between Socioenvironmental Stressors, Allostatic Load and Breast Cancer Related Lymphedema



Introduction

Breast cancer-related lymphedema (BCRL) is a common debilitating complication following breast cancer treatment, with incidence rates ranging between 5–40% depending on risk factors such as obesity, infections, receipt of radiation therapy, chemotherapy, and extent of axillary lymph node dissection [1–3]. Recent studies have highlighted the influence of socioenvironmental stressors, defined as the social and physical aspects of an individual’s living and working conditions, on the development and severity of BCRL [4, 5]. For example, rurality, low income, and poor social support have been associated with the development of BCRL [4, 5]. Additionally, comorbidities such as obesity, which have previously been linked to adverse socioenvironmental stressors, have also been associated with a higher risk of developing BCRL [6, 7]. Nonetheless, despite growing evidence suggesting an association between socioenvironmental stressors and lymphedema, there is a paucity of research examining the biological correlates of these stressors, such as allostatic load, in the context of BCRL [8].

Allostatic load (AL) is a multisystem construct incorporating biomarkers from various physiological domains, including the metabolic, neuroendocrine, immune, and cardiovascular systems, to measure physiological dysregulation secondary to chronic activation of the hypothalamic–pituitary–adrenal (HPA) axis and the sympathetic-adrenal-medullary (SAM) pathway [9]. AL has been linked to various adverse health outcomes, including cancer [10–13]. Previous studies have demonstrated that high AL, an indicator of greater physiologic dysregulation, is associated with more advanced disease severity and increased all-cause mortality in patients with breast cancer and other solid tumors [14–16]. Moreover, elevated AL has been associated with socioenvironmental factors such as race, socioeconomic status, and neighborhood characteristics

[14, 16]. Our recent examination of AL and 30-day post-operative complications in patients with breast cancer showed an association between high AL and higher rates of developing postoperative complications [17]. Furthermore, mediation analysis suggested that AL may influence the development of postoperative complications indirectly through comorbidities and directly through an independent pathway [17]. Taken together, these studies suggest AL might be a plausible biological intermediary between socioenvironmental stressors and the development of chronic post-treatment complications such as BCRL (Fig. 1).

The objective of this study was to understand the association between AL at diagnosis and lymphedema development in a cohort of breast cancer survivors who received surgical treatment. We hypothesize that patients with high allostatic load scores at diagnosis will have higher odds of developing lymphedema than those with low allostatic load scores.

Methods

Data source

Women diagnosed with stage I–III breast cancer from January 1st, 2012, through December 31st, 2020, who underwent operative management were identified in The Ohio State University Cancer registry and The Ohio State University Comprehensive Cancer Center electronic medical records (IHIS). Patients diagnosed with ductal carcinoma in situ (stage 0), metastatic disease (stage IV), recurrent breast cancer, unknown breast cancer subtype, and individuals who did not receive surgical management, had missing lymphedema information, or had lower extremity lymphedema were excluded. (Fig. 2).




Fig. 2 Study Schema

Study measures

Sociodemographic characteristics

Sociodemographic variables included age, race (White, Black, or Other), ethnicity (Hispanic or non-Hispanic), marital status (single, married/living as married or widowed/separated/divorced), insurance (Private, Medicaid, Medicare, Other), smoking history (yes or no) and alcohol use (yes or no). All racial and ethnic categories are self-reported. Patients who self-identified as Asian, American Indian, Alaskan Native, Other Pacific Islander, Native Hawaiian, or multiracial were collapsed into the “Other” category due to small sample sizes. In this study, race is a sociopolitical construct, not a measure of genetic ancestry [18]. The Charlson Comorbidity Index (CCI) was categorized into 0, 1–3, or 4+ and was modified to exclude cancer as a contributor to comorbidity [19].

Clinical and treatment characteristics

Patient stage (clinical and pathological), hormone receptor status (estrogen and progesterone receptors [HR]), and human epidermal growth factor receptor 2 (HER2) status were obtained from the electronic medical record. Molecular subtypes were categorized into HR positive/HER2 negative (HR +/HER2-), HR +/HER2 +, HR-/HER2 + or HR-/HER2-. Breast (mastectomy, lumpectomy, or both) and

axillary (sentinel lymph node biopsy (SLNB) only, axillary lymph node dissection (ALND) only, or both SLNB and ALND) surgeries were included. Chemotherapy and radiation therapy were dichotomized as yes or no.

Allostatic load

There is currently no consensus on standard biomarkers for calculating allostatic load[20]. This study uses biomarkers across four physiologic systems commonly reported in the literature: cardiovascular (heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressures), metabolic (body mass index (BMI), alkaline phosphatase (ALP), glucose, albumin), renal (creatinine and blood urea nitrogen (BUN)), and immunologic (white blood cell count (WBC)) [20]. Biomarkers were collected up to 12 months before or 6 months following biopsy-proven cancer diagnosis in the electronic medical record. Distributions of these biomarkers were divided into quartiles, and values in the worst quartile of the cohort were given a point [21]. Specifically, biomarkers ≥ 75 th percentile for HR, SBP, DBP, ALP, glucose, creatinine, BUN, and WBC were each given a point. In contrast, albumin ≤ 25 th percentile was assigned a point. Patients with a BMI of < 18.5 or ≥ 30 were also given a point. Points were summed and then dichotomized into low vs. high based on the median sum score (AL 2.0) and categorized into quartiles (Q1 with sum 0–1, Q2 with sum 2, Q3 with sum 3–4,

Q4 with sum 5+). Higher scores were indicative of worse physiological disturbance.

Study outcome—lymphedema

The primary outcome was the development of breast or ipsilateral upper extremity lymphedema (yes/no). Patients with a history of breast cancer diagnosed between 01/01/2012 and 12/31/2020 who developed lymphedema following their initial treatment (surgery or chemotherapy) were identified through the electronic medical record (EMR). Specifically, a data analyst queried patient notes for the term “lymphedema staging,” and physical therapy notes were subsequently reviewed to confirm the diagnosis and severity of lymphedema. Individuals with either breast-only or upper-extremity lymphedema were coded as ‘yes’ for lymphedema. Patients with lower extremity lymphedema were excluded from the study. The highest grade was selected for patients with multiple grades. Grades were dichotomized as 0/1 or 2/3.

Statistical analysis

Multiple imputations by chained equations were used to account for missing values [22]. Ten imputed datasets were created using logistic regression-based imputation models for binary and ordinal variables, discriminant function for non-ordered variables, and regression-based projected mean matching for continuous variables. Imputation-corrected parameters and standard errors (SEs) were combined using Rubin’s rule [23].

Sociodemographic, clinical, and treatment variables were summarized using descriptive statistics, with medians and interquartile ranges (IQRs) for continuous variables and frequencies and percentages for categorical variables. Differences between groups based on lymphedema development were calculated using Wilcoxon rank-sum, chi-square, or Fisher’s exact test.

Crude and adjusted logistic regression analyses were performed to test the association between AL and the development of lymphedema. In addition, among patients who developed lymphedema, crude and adjusted models assessed lymphedema grade (2/3 vs. 0/1) as the outcome with AL as the exposure. To increase the comparability of our results, we included AL as a continuous, binary, and quartile variable in all fitted regression models.

Secondary analysis examined the relationship between lymphedema and each of the 10 AL biomarkers using established clinical cut-offs [16]. To examine the value of the composite AL as an independent predictor of lymphedema, univariate and multivariable binary logistic regressions modeled each AL biomarker and the composite AL score (as a 1-unit increase).

All analyses were performed using the SAS software (version 9.4; SAS Institute, Cary, NC, USA). A two-sided p-value of less than 0.05 was considered statistically significant. The authors used ChatGPT and Grammarly to improve the language and readability during the preparation of this manuscript.

Results

Description of study cohort

3,609 patients met the study criteria, of whom 18.86% (n = 681) developed lymphedema. Patients who developed BCRL were younger than those who did not develop lymphedema (lymphedema 55.2 years (interquartile range (IQR) 47.1 years–64.0 years, no lymphedema 59.1 years (IQR 49.7 years –67.1 years). Compared with patients without lymphedema, a higher proportion of patients who developed lymphedema were racialized as Black (lymphedema 11.89% vs. no lymphedema 7.38%, $p < 0.0001$) and had Medicaid insurance (12.19% vs. 6.97%, $p < 0.0001$) (Table 1). Additionally, patients who developed lymphedema had more aggressive breast cancer molecular subtypes ($p = 0.0033$) and higher disease stages ($p < 0.0001$) than those without lymphedema. A higher percentage of patients with lymphedema received chemotherapy (lymphedema 63.14% vs. no lymphedema 37.77%, $p < 0.0001$), radiation therapy (lymphedema 66.62% vs. no lymphedema 57.82%, $p < 0.01$) and underwent ALND (lymphedema 67.11% vs. 5.82%, $p < 0.0001$). There was no significant difference in the CCI based on lymphedema development ($p = 0.515$).

Allostatic load and lymphedema

As a binary variable (low vs. high AL), a higher proportion of patients who developed lymphedema had higher AL (53.58%) than those without lymphedema (46.90%, $p < 0.001$). Patients with high AL had 28% higher odds of developing lymphedema (OR = 1.28, 95% CI: 1.06–1.55) than those with low AL (Table 2). Similarly, patients in the highest AL quartile (Q4 OR = 1.51, 95% CI: 1.09–2.08) had 51% higher odds of developing lymphedema than those in the lowest AL quartile (Q1). A one-unit increase in AL was associated with 10% higher odds of lymphedema (OR = 1.10, 95% CI: 1.04–1.16). There was no significant association between the lymphedema grade and AL (Table 3). After controlling for individual AL biomarkers, sociodemographic characteristics, and treatment receipt, composite AL and BMI were the only biomarker variables significantly associated with lymphedema (Supplementary Table 1).

Of note, consistent with existing literature, patients with high AL in this study cohort were more likely to be older,

Table 1 Sociodemographic, clinical and treatment characteristics based on lymphedema development

Patient Characteristics, n (%)	Total Sample (N=3609)	Lymphedema (n=681)	No Lymphedema (n=2928)	P-value
Age at diagnosis (in years) Median (Q ₁ , Q ₃)	58.5 (49.0, 66.5)	55.2 (47.1, 64.0)	59.1 (49.7, 67.1)	<0.0001
Race	3166 (87.73%)	563 (82.76%)	2603 (88.90%)	<0.0001
White	297 (8.23%)	81 (11.89%)	216 (7.38%)	
Black	146 (4.05%)	37 (5.43%)	109 (3.72%)	
Other				
Ethnicity	40 (1.11%)	12 (1.76%)	28 (0.96%)	0.0704
Hispanic	3569 (98.89%)	669 (98.19%)	2990 (99.04%)	
Non-Hispanic				
Marital Status	499 (13.83%)	107 (15.71%)	392 (13.39%)	0.2686
Single	2328 (64.51%)	433 (63.58%)	1895 (64.72%)	
Married/living as married	782 (21.67%)	141 (20.70%)	641 (21.89%)	
Widowed, separated or divorced				
Insurance	2159 (59.82%)	422 (61.97%)	1737 (59.32%)	<0.0001
Private	287 (7.95%)	83 (12.19%)	204 (6.97%)	
Medicaid	1114 (30.87%)	167 (24.52%)	947 (32.34%)	
Medicare	49 (1.36%)	9 (1.32%)	40 (1.37%)	
Other				
Smoking History	2254 (62.44%)	441 (64.79%)	1812 (61.90%)	0.2468
Never	1355 (37.56%)	240 (35.21%)	1116 (38.10%)	
Current or Former				
Alcohol Use	1686 (46.72%)	355 (52.09%)	1331 (45.47%)	0.0019
Never	1923 (53.28%)	326 (47.91%)	1597 (54.53%)	
Current or former				
Charlson Comorbidity index	2879 (79.77%)	541 (79.44%)	2338 (79.85%)	0.5152
0	655 (18.15%)	122 (17.91%)	533 (18.20%)	
1–3	75 (2.08%)	18 (2.64%)	57 (1.95%)	
≥4				
Estrogen receptor status	662 (18.34%)	155 (22.76%)	507 (17.32%)	0.0009
Negative	2947 (81.66%)	526 (77.24%)	2421 (82.68%)	
Positive				
Progesterone receptor	1013 (28.07%)	222 (32.60%)	791 (27.02%)	0.0035
Negative	2596 (71.93%)	459 (67.40%)	2137 (72.98%)	
Positive				
Subtype	2303 (63.81%)	399 (58.59%)	1904 (65.03%)	0.0033
HR +/HER2-	645 (17.87%)	127 (18.65%)	518 (17.69%)	
HR +/HER2 +	495 (13.72%)	120 (17.62%)	375 (12.81%)	
HR-/HER2-	166 (4.60%)	35 (5.14%)	131 (4.47%)	
HR-/HER2 +				
Cancer Stage	2497 (69.19%)	357 (52.42%)	2140 (73.09%)	<0.0001
1	1018 (28.21%)	276 (40.53%)	742 (25.34%)	
2	94 (2.60%)	48 (7.05%)	46 (1.57%)	
3				
Chemotherapy	1536 (42.56%)	430 (63.14%)	1106 (37.77%)	<0.0001
Yes	2073 (57.44%)	251 (36.86%)	1822 (62.23%)	
No				
Radiation Therapy	2150 (59.57%)	457 (67.11%)	1693 (57.82%)	<0.0001
Yes	1459 (40.43%)	224 (32.89%)	1235 (42.18%)	
No				
Breast surgery type	1467 (40.65%)	327 (48.02%)	1140 (38.93%)	<0.0001
Mastectomy	2032 (56.30%)	319 (46.84%)	1713 (58.50%)	
Lumpectomy	110 (3.05%)	35 (5.14%)	75 (2.56%)	
Both				
Lymph node surgery	1411 (39.10%)	159 (23.35%)	1252 (42.76%)	<0.0001
Sentinel lymph node biopsy only	226 (6.26%)	132 (19.38%)	94 (3.21%)	
Axillary lymph node dissection only	1972 (54.64%)	390 (57.27%)	1582 (54.03%)	
Both SLNB + ALND				

Table 1 (continued)

Patient Characteristics, n (%)	Total Sample (N = 3609)	Lymphedema (n = 681)	No Lymphedema (n = 2928)	P-value
Allostatic load Median (IQR)	1.92 (0.80–3.15)	2.18 (1.02–3.49)	1.87 (0.76–3.05)	0.0001
Allostatic load (binary)	1871 (51.84%)	316 (46.42%)	1555 (53.10%)	0.0025
Low (≤ 2)	1738 (48.16%)	365 (53.58%)	1373 (46.90%)	
High (> 2)				
Allostatic load (quartiles)	1035 (28.69%)	168 (24.65%)	867 (29.62%)	0.0076
Q1 (0–1)	836 (23.16%)	148 (21.76%)	688 (23.48%)	
Q2 (2)	1266 (35.09%)	256 (37.61%)	1010 (34.50%)	
Q3 (3–4)	472 (13.07%)	103 (15.98%)	363 (12.39%)	
Q4 (5+)				

Table 2 Association between AL and development of lymphedema (n = 3,609)*

	Crude OR (95% CI)	Adjusted OR (95% CI)
AL (continuous) 1-unit increase	1.10 (1.05–1.16)	1.10 (1.04–1.16)
AL (in quartiles)	Ref	Ref
Q1 (0–1)	1.11 (0.87–1.43)	1.09 (0.84–1.43)
Q2 (2)	1.31 (1.05–1.64)	1.28 (1.00–1.64)
Q3 (3–4)	1.55 (1.16–2.06)	1.51 (1.09–2.08)
Q4 (5+)		
AL (binary)	Ref	Ref
Low (≤ 2)	1.31 (1.10–1.56)	1.28 (1.06–1.55)
High (> 2)		

*Adjusted for age, race, chemotherapy, radiation therapy, breast surgery type, and lymph node surgery type

Table 3 Association between AL and Lymphedema Grade (n = 226)*

	Crude OR (95% CI)	Adjusted OR (95% CI)
AL (continuous) 1-unit increase	1.07 (0.91–1.26)	1.02 (0.85–1.23)
AL (in quartiles)	Ref	Ref
Q1 (0–1)	0.91 (0.40–2.10)	0.86 (0.35–2.12)
Q2 (2)	1.64 (0.80–3.34)	1.60 (0.73–3.50)
Q3 (3–4)	1.20 (0.51–2.79)	0.92 (0.36–2.35)
Q4 (5+)		
AL (binary)	Ref	Ref
Low (≤ 2)	1.56 (0.91–2.68)	1.46 (0.80–2.67)
High (> 2)		

*Adjusted for age, race, chemotherapy, radiation therapy, breast surgery type and lymph node surgery

racialized as Black, Medicaid insured, unpartnered, have more aggressive molecular subtypes, higher stages of disease, and a higher CCI than those with low AL (Supplementary Table 2).

Discussion

In this large retrospective analysis of patients who received surgical management for breast cancer, elevated allostatic load was associated with a higher probability of developing BCRL. Moreover, in models controlling for individual AL biomarkers, high AL remained significantly associated with the development of BCRL. These results suggest that AL may contribute to the development of BCRL independent of its individual biomarker components.

The pathophysiology of BCRL suggests that the extent of axillary surgery, radiation therapy, and receipt of taxane chemotherapy cause mechanical disruptions or pathologic changes (e.g., fibrosis) to the lymphatic system, resulting in lymphedema [3, 24]. A plausible mechanistic pathway of how AL influences lymphedema development is concomitantly through its individual biomarkers and as a common factor [25, 26]. For example, biomarkers frequently used to calculate AL, such as albumin, blood glucose, inflammatory biomarkers (e.g., interleukin 6) and BMI have all been implicated in wound healing or BCRL [27–31]. Similarly, our supplementary analysis showed an association between 1) AL and BCRL, and 2) BMI and BRCL after controlling for the individual biomarkers used to calculate AL. Additionally, in our prior examination of AL and acute post-operative complications (e.g., hematoma) in patients with breast cancer, AL was associated with the development of postoperative complications directly and indirectly through a shared pathway with comorbidities [17, 32]. This is particularly relevant, as Konishi et al.'s study on factors associated with arm lymphedema post-surgery found that postoperative bleeding increases the likelihood of arm lymphedema [33]. Collectively, these studies suggest AL may work through a bifactor model where AL contributes to treatment-related complications independent of its constituent components [25, 26].

The weathering hypothesis and ecosocial theory may provide conceptual frameworks for the internalization of socioenvironmental stressors through mechanisms such as AL. Both conceptual frameworks postulate that chronic

exposure to adverse socioenvironmental stressors results in physiologic and molecular changes with implications for disease distribution within populations [34, 35]. For patients with breast cancer, studies indicate that exposure to adverse socioenvironmental factors, such as low educational attainment, lack of medical insurance, and low income, are associated with BCRL development [36]. In this study, a higher percentage of Black and Medicaid-insured patients had lymphedema compared to other racial categories or insurance types. Also consistent with existing literature, patients encountering adverse socioenvironmental conditions, such as Black women, those with Medicaid insurance, and unpartnered individuals, were more likely to have high AL compared to White women, those with private insurance, and those who were partnered [14, 16, 37, 38]. Overall, this study's findings and existing literature highlight relationships between environmental exposures, their impact on physiology, and potential implications for treatment outcomes.

The percentage of patients developing lymphedema in this study is consistent with prior studies examining lymphedema in patients with breast cancer. In their systematic review and meta-analysis of lymphedema after breast cancer, Disipio et al. estimated an overall BCRL incidence of 16.6% and an incidence range between 8.4% and 24.1% for prospective studies [1]. Similarly, in this study, approximately 19% of patients developed BCRL. Patient (e.g., Black race) characteristics and treatment-related factors (e.g., undergoing axillary lymph node dissection) more common in patients with BCRL were also consistent with existing literature [39, 40].

The strengths of this study include a large, diverse patient cohort and the use of a robust measure of AL that has been used in multiple studies [14, 15, 17, 41]. Moreover, the AL biomarkers used in this study are routinely collected in the clinical care of patients with cancer, allowing others to easily replicate this study in other cancer populations. Secondary analysis confirmed AL was associated with the outcome of interest even after controlling for individual AL biomarkers and sociodemographic, clinical, and treatment factors, enhancing our findings' internal validity.

However, the study also has some limitations. As a single-institution retrospective study, the generalizability of our findings may be limited. Additionally, the retrospective nature introduces potential selection biases. The use of the electronic medical record introduces additional limitations, as it may not capture care provided outside of OSUCCC and is susceptible to exposure misclassification [42]. Future prospective, multi-center studies are needed to validate our findings and explore the mechanisms underlying the association between AL and BCRL.

Conclusion

This study provides novel evidence of the association between AL and BCRL development. Moreover, it highlights the importance of considering the impact of chronic exposure to socioenvironmental stressors, potentially manifesting in measures such as AL, in the context of lymphedema. Future research should focus on elucidating the specific pathways through which AL influences lymphedema development and evaluating the effectiveness of AL-targeted interventions in reducing BCRL risk and improving outcomes for breast cancer survivors.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1007/s00520-025-09362-4>.

Acknowledgements Samilia Obeng-Gyasi was funded by Conquer Cancer Breast Cancer Research Foundation Advanced Clinical Research Award for Diversity and Inclusion in Breast Cancer Research, The Society of University Surgeons, and The American Cancer Society (RSG-22-106-01-CSCT). Dionisia Quiroga is funded by a Robert A. Winn Diversity in Clinical Trials Career Development Award, funded by Bristol Myers Squibb Foundation.

Author contributions Yevgeniya Gokun, Mohamed I Elsaid, and Samilia Obeng-Gyasi contributed to the study's conception and design. Yevgeniya Gokun also prepared materials, collected data, and analyzed the data. Barnabas Obeng-Gyasi drafted the manuscript and all authors critically revised it for intellectual content. All authors approved the final version of the manuscript.

Funding Samilia Obeng-Gyasi was funded by Conquer Cancer Breast Cancer Research Foundation Advanced Clinical Research Award for Diversity and Inclusion in Breast Cancer Research, The Society of University Surgeons, and The American Cancer Society (RSG-22-106-01-CSCT). Dionisia Quiroga is funded by a Robert A. Winn Diversity in Clinical Trials Career Development Award, funded by Bristol Myers Squibb Foundation.

Data availability The data from this study includes Health Insurance Portability and Accountability Act data and cannot be publicly shared.

Declarations

Ethical approval This study was approved by the Ohio State University Office of Responsible Research Practices and complied with all relevant ethical regulations including the Declaration of Helsinki.

Consent to participate The consent to participate was waived as this is a retrospective study:

Consent to publish The consent to publish is waived as this is a retrospective study.

Competing interests The authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes

were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol* 14(6):500–515
- Togawa K, Ma H, Sullivan-Halley J, Neuhaus ML, Imai I, Baumgartner KB, Smith AW, Alfano CM, McTiernan A, Ballard-Barbash R et al (2014) Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. *Breast Cancer Res: BCR* 16(4):414
- Nguyen TT, Hoskin TL, Habermann EB, Chevillat AL, Boughey JC (2017) Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. *Ann Surg Oncol* 24(10):2972–2980
- Sayko O, Pezzin LE, Yen TW, Nattinger AB (2013) Diagnosis and treatment of lymphedema after breast cancer: a population-based study. *PM R* 5(11):915–923
- Koelmeyer LA, Gaitatzis K, Dietrich MS, Shah CS, Boyages J, McLaughlin SA, Taback B, Stollendorf DP, Elder E, Hughes TM et al (2022) Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. *Cancer* 128(18):3408–3415
- Sayegh HE, Asdourian MS, Swaroop MN, Brunelle CL, Skolny MN, Salama L, Taghian AG (2017) Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions. *Curr Breast Cancer Rep* 9(2):111–121
- Javed Z, Valero-Elizondo J, Maqsood MH, Mahajan S, Taha MB, Patel KV, Sharma G, Hagan K, Blaha MJ, Blankstein R et al (2022) Social determinants of health and obesity: findings from a national study of US adults. *Obesity (Silver Spring)* 30(2):491–502
- Invernizzi M, Lopez G, Michelotti A, Venetis K, Sajjadi E, De Mattos-Arruda L, Ghidini M, Runza L, de Sire A, Boldorini R et al (2020) Integrating biological advances into the clinical management of breast cancer related lymphedema. *Front Oncol* 10:422
- McEwen BS (2000) Allostasis and allostatic load: implications for neuropsychopharmacology. *Neuropsychopharmacology* 22(2):108–124
- Kinlein SA, Karatsoreos IN (2020) The hypothalamic-pituitary-adrenal axis as a substrate for stress resilience: Interactions with the circadian clock. *Front Neuroendocrinol* 56:100819
- Guan Y, Shen J, Lu J, Fuemmeler BF, Shock LS, Zhao H (2023) Association between allostatic load and breast cancer risk: a cohort study. *Breast Cancer Res: BCR* 25(1):155
- Schulz KH, Gold S (2006) Psychological stress, immune function and disease development. The psychoneuroimmunologic perspective. *Bundesgesundheitsbl Gesundheitsforsch Gesundheitschutz* 49(8):759–772
- Schulz KH, Heesen C, Gold SM (2005) The concept of allostasis and allostatic load: psychoneuroimmunological findings. *Psychother Psychosom Med Psychol* 55(11):452–461
- Chen JC, Elsaid MI, Handley D, Plascak JJ, Andersen BL, Carson WE, Pawlik TM, Fareed N, Obeng-Gyasi S (2024) Association between neighborhood opportunity, allostatic load, and all-cause mortality in patients with breast cancer. *J Clin Oncol: Off J Am Soc Clin Oncol* Jco2300907
- Chen JC, Handley D, Elsaid MI, Plascak JJ, Andersen BL, Carson WE, Pawlik TM, Carlos RC, Obeng-Gyasi S (2024) The implications of racialized economic segregation and allostatic load on mortality in patients with breast cancer. *Ann Surg Oncol* 31(1):365–375
- Obeng-Gyasi S, Elsaid MI, Lu Y, Chen J, Carson WE, Ballinger TJ, Andersen BL (2023) Association of allostatic load with all-cause mortality in patients with breast cancer. *JAMA Netw Open* 6(5):e2313989–e2313989
- Chen JC, Elsaid MI, Handley D, Anderson L, Andersen BL, Carson WE, Beane JD, Kim A, Skoracki R, Pawlik TM et al (2024) Allostatic load as a predictor of postoperative complications in patients with breast cancer. *NPJ Breast Cancer* 10(1):44
- Kittles RA, Weiss KM (2003) Race, ancestry, and genes: implications for defining disease risk. *Annu Rev Genomics Hum Genet* 4:33–67
- Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40(5):373–383
- Duong MT, Bingham BA, Aldana PC, Chung ST, Sumner AE (2017) Variation in the calculation of allostatic load score: 21 examples from NHANES. *J Racial Ethn Health Disparities* 4(3):455–461
- Juster RP, Russell JJ, Almeida D, Picard M (2016) Allostatic load and comorbidities: a mitochondrial, epigenetic, and evolutionary perspective. *Dev Psychopathol* 28(4pt1):1117–1146
- Liu Y, De A (2015) Multiple Imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. *Int J Stat Med Res* 4(3):287–295
- Rubin DB (1976) Inference and missing data. *Biometrika* 63:581–592
- Grada AA, Phillips TJ (2017) Lymphedema: pathophysiology and clinical manifestations. *J Am Acad Dermatol* 77(6):1009–1020
- Wiley JF, Gruenewald TL, Karlamangla AS, Seeman TE (2016) Modeling multisystem physiological dysregulation. *Psychosom Med* 78(3):290–301
- Wiley JF, Gruenewald TL, Karlamangla AS, Seeman TE (2017) The authors reply: pursuing the optimal operationalization of allostatic load. *Psychosom Med* 79(1):119–121
- Helyer LK, Varnic M, Le LW, Leong W, McCready D (2010) Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. *Breast J* 16(1):48–54
- Ridner SH, Dietrich MS, Kidd N (2011) Breast cancer treatment-related lymphedema self-care: education, practices, symptoms, and quality of life. *Support Care Cancer: Off J Multinat Assoc Support Care Cancer* 19(5):631–637
- Vang AR, Shaitelman SF, Rasmussen JC, Chan W, Sevcik-Muraca EM, Aldrich MB (2023) Plasma cytokines/chemokines as predictive biomarkers for lymphedema in breast cancer patients. *Cancers (Basel)* 15(3):676
- Singh S, Young A, McNaught C-E (2017) The physiology of wound healing. *Surg Infect (Larchmt)* 35(9):473–477
- Doweiko JP, Nompleggi DJ (1991) The role of albumin in human physiology and pathophysiology, Part III: Albumin and disease states. *J Parenter Enteral Nutr* 15(4):476–483
- Gouin JP, Kiecolt-Glaser JK (2012) The impact of psychological stress on wound healing: methods and mechanisms. *Crit Care Nurs Clin North Am* 24(2):201–213
- Konishi T, Tanabe M, Michihata N, Matsui H, Nishioka K, Fushimi K, Seto Y, Yasunaga H (2023) Risk factors for arm

- lymphedema following breast cancer surgery: a Japanese nationwide database study of 84,022 patients. *Breast Cancer (Tokyo, Japan)* 30(1):36–45
34. Geronimus AT, Hicken M, Keene D, Bound J (2006) “Weathering” and age patterns of allostatic load scores among blacks and whites in the United States. *Am J Public Health* 96(5):826–833
 35. Krieger N (2001) Theories for social epidemiology in the 21st century: an ecosocial perspective. *Int J Epidemiol* 30(4):668–677
 36. Norman SA, Localio AR, Kallan MJ, Weber AL, Simoes Torpey HA, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ (2010) Risk factors for lymphedema after breast cancer treatment. *Cancer Epidemiol Biomark Prev* 19(11):2734–2746
 37. Parente V, Hale L, Palermo T (2013) Association between breast cancer and allostatic load by race: National Health and Nutrition Examination Survey 1999–2008. *Psychooncology* 22(3):621–628
 38. Rote S (2017) Marital disruption and allostatic load in late life. *J Aging Health* 29(4):688–707
 39. Rochlin DH, Barrio AV, McLaughlin S, Van Zee KJ, Woods JF, Dayan JH, Coriddi MR, McGrath LA, Bloomfield EA, Boe L et al (2023) Feasibility and clinical utility of prediction models for breast cancer-related lymphedema incorporating racial differences in disease incidence. *JAMA Surg* 158(9):954–964
 40. Heller DR, Axelrod B, Sevilimedu V, Morrow M, Mehrara BJ, Barrio AV (2024) Quality of life after axillary lymph node dissection among racial and ethnic minority women. *JAMA Surg* 159(6):668–676
 41. Borho L, Bao R, Elishaev E, Dinkins KD, O’Brien EE, Berger J, Boisen M, Comerc J, Courtney-Brooks M, Edwards RP et al (2024) Association of allostatic load with overall survival in epithelial ovarian cancer. *Gynecol Oncol* 186:204–210
 42. Young JC, Conover MM, Funk MJ (2018) Measurement error and misclassification in electronic medical records: methods to mitigate bias. *Curr Epidemiol Rep* 5(4):343–356

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.